Participant flow

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

   id

   FG000

   title

   Diffuse Large B Cell Lymphoma

2. description

   Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

   id

   FG001

   title

   Classical Hodgkin Lymphoma

3. description

   Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

   id

   FG002

   title

   Peripheral T Cell Lymphoma

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         31

      2. group Id

         FG001

         num Subjects

         30

      3. group Id

         FG002

         num Subjects

         21

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         31

      2. group Id

         FG001

         num Subjects

         30

      3. group Id

         FG002

         num Subjects

         21

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice